Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells

Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who receiv...

Full description

Bibliographic Details
Main Authors: Alexandra Dreyzin, Sandhya R. Panch, Haneen Shalabi, Bonnie Yates, Steven L. Highfill, Ping Jin, David Stroncek, Nirali N. Shah
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Molecular Therapy: Methods & Clinical Development
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2329050122001772
_version_ 1797978784109953024
author Alexandra Dreyzin
Sandhya R. Panch
Haneen Shalabi
Bonnie Yates
Steven L. Highfill
Ping Jin
David Stroncek
Nirali N. Shah
author_facet Alexandra Dreyzin
Sandhya R. Panch
Haneen Shalabi
Bonnie Yates
Steven L. Highfill
Ping Jin
David Stroncek
Nirali N. Shah
author_sort Alexandra Dreyzin
collection DOAJ
description Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who received cryopreserved versus fresh CAR T cells for treatment of B cell leukemia across two cohorts of pediatric and young adult patients: those who received anti-CD22 CAR T cells and those who received bispecific anti-CD19/22 CAR T cells. Manufacturing methods were consistent within each trial but differed between the two trials, allowing for exploration of cryopreservation within different manufacturing platforms. Among 40 patients who received anti-CD22 CAR T cells (21 cryopreserved cells and 19 fresh), there were no differences in in vivo expansion, persistence, incidence of toxicities, or disease response between groups with cryopreserved and fresh CAR T cells. Among 19 patients who received anti-CD19/22 CAR T cells (11 cryopreserved and 8 fresh), patients with cryopreserved cells had similar expansion, toxicity incidence, and disease response, with decreased CAR T cell persistence. Overall, our data demonstrate efficacy of cryopreserved CAR T cells as comparable to fresh infusions, supporting cryopreservation, which will be crucial for advancing the field of cell therapy.
first_indexed 2024-04-11T05:28:31Z
format Article
id doaj.art-b7798ef47ea843b29b8ef539a38ccb2c
institution Directory Open Access Journal
issn 2329-0501
language English
last_indexed 2024-04-11T05:28:31Z
publishDate 2023-03-01
publisher Elsevier
record_format Article
series Molecular Therapy: Methods & Clinical Development
spelling doaj.art-b7798ef47ea843b29b8ef539a38ccb2c2022-12-23T04:41:13ZengElsevierMolecular Therapy: Methods & Clinical Development2329-05012023-03-01285161Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cellsAlexandra Dreyzin0Sandhya R. Panch1Haneen Shalabi2Bonnie Yates3Steven L. Highfill4Ping Jin5David Stroncek6Nirali N. Shah7Center for Cancer and Blood Disorders, Children’s National Hospital, Washington, DC 20010, USADivision of Hematology, Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USAPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USAPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USADepartment of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Bethesda, MD 20892, USADepartment of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Bethesda, MD 20892, USADepartment of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Bethesda, MD 20892, USA; Corresponding author David Stroncek, MD, Department of Transfusion Medicine and Cellular Engineering, Center for Cellular Engineering, NIH Clinical Center, NIH, Building 10, Room 1C711, 10 Center Drive, Bethesda, MD 20892, USA.Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA; Corresponding author Nirali N. Shah, MD, MHSc, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 1W-3750, 9000 Rockville Pike MSC 1104, Bethesda, MD 20892, USA.Cryopreservation of chimeric antigen receptor (CAR) T cells facilitates shipment, timing of infusions, and storage of subsequent doses. However, reports on the impact of cryopreservation on CAR T cell efficacy have been mixed. We retrospectively compared clinical outcomes between patients who received cryopreserved versus fresh CAR T cells for treatment of B cell leukemia across two cohorts of pediatric and young adult patients: those who received anti-CD22 CAR T cells and those who received bispecific anti-CD19/22 CAR T cells. Manufacturing methods were consistent within each trial but differed between the two trials, allowing for exploration of cryopreservation within different manufacturing platforms. Among 40 patients who received anti-CD22 CAR T cells (21 cryopreserved cells and 19 fresh), there were no differences in in vivo expansion, persistence, incidence of toxicities, or disease response between groups with cryopreserved and fresh CAR T cells. Among 19 patients who received anti-CD19/22 CAR T cells (11 cryopreserved and 8 fresh), patients with cryopreserved cells had similar expansion, toxicity incidence, and disease response, with decreased CAR T cell persistence. Overall, our data demonstrate efficacy of cryopreserved CAR T cells as comparable to fresh infusions, supporting cryopreservation, which will be crucial for advancing the field of cell therapy.http://www.sciencedirect.com/science/article/pii/S2329050122001772cell therapyCAR Tclinical outcomescryopreservationCAR T manufacturingcytokine release syndrome
spellingShingle Alexandra Dreyzin
Sandhya R. Panch
Haneen Shalabi
Bonnie Yates
Steven L. Highfill
Ping Jin
David Stroncek
Nirali N. Shah
Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
Molecular Therapy: Methods & Clinical Development
cell therapy
CAR T
clinical outcomes
cryopreservation
CAR T manufacturing
cytokine release syndrome
title Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
title_full Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
title_fullStr Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
title_full_unstemmed Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
title_short Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
title_sort cryopreserved anti cd22 and bispecific anti cd19 22 car t cells are as effective as freshly infused cells
topic cell therapy
CAR T
clinical outcomes
cryopreservation
CAR T manufacturing
cytokine release syndrome
url http://www.sciencedirect.com/science/article/pii/S2329050122001772
work_keys_str_mv AT alexandradreyzin cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT sandhyarpanch cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT haneenshalabi cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT bonnieyates cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT stevenlhighfill cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT pingjin cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT davidstroncek cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells
AT niralinshah cryopreservedanticd22andbispecificanticd1922cartcellsareaseffectiveasfreshlyinfusedcells